Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run
This report highlights a trio of gene therapy names with additional upside for investors with an 18-month time horizon. BLUE should net at least $150,000 per patient with demand from thousands of patients annually by 2020-2022.
from Biotech News
0 Comments